Artivion (AORT) Competitors $26.75 +0.42 (+1.60%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AORT vs. AXNX, NVST, TMDX, NARI, LIVN, ENOV, IRTC, SLNO, CNMD, and TNDMShould you be buying Artivion stock or one of its competitors? The main competitors of Artivion include Axonics (AXNX), Envista (NVST), TransMedics Group (TMDX), Inari Medical (NARI), LivaNova (LIVN), Enovis (ENOV), iRhythm Technologies (IRTC), Soleno Therapeutics (SLNO), CONMED (CNMD), and Tandem Diabetes Care (TNDM). These companies are all part of the "medical equipment" industry. Artivion vs. Axonics Envista TransMedics Group Inari Medical LivaNova Enovis iRhythm Technologies Soleno Therapeutics CONMED Tandem Diabetes Care Artivion (NYSE:AORT) and Axonics (NASDAQ:AXNX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership. Which has more volatility and risk, AORT or AXNX? Artivion has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500. Comparatively, Axonics has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Do analysts prefer AORT or AXNX? Artivion currently has a consensus price target of $30.60, suggesting a potential upside of 14.39%. Axonics has a consensus price target of $71.00, suggesting a potential upside of 0.90%. Given Artivion's stronger consensus rating and higher probable upside, equities analysts clearly believe Artivion is more favorable than Axonics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artivion 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Axonics 0 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is AORT or AXNX more profitable? Axonics has a net margin of -0.42% compared to Artivion's net margin of -2.22%. Artivion's return on equity of 3.81% beat Axonics' return on equity.Company Net Margins Return on Equity Return on Assets Artivion-2.22% 3.81% 1.39% Axonics -0.42%-0.27%-0.24% Does the media prefer AORT or AXNX? In the previous week, Axonics had 1 more articles in the media than Artivion. MarketBeat recorded 2 mentions for Axonics and 1 mentions for Artivion. Axonics' average media sentiment score of 1.58 beat Artivion's score of -0.27 indicating that Axonics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Axonics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals and insiders believe in AORT or AXNX? 86.4% of Artivion shares are owned by institutional investors. Comparatively, 99.5% of Axonics shares are owned by institutional investors. 8.1% of Artivion shares are owned by company insiders. Comparatively, 1.9% of Axonics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer AORT or AXNX? Axonics received 153 more outperform votes than Artivion when rated by MarketBeat users. However, 77.78% of users gave Artivion an outperform vote while only 66.67% of users gave Axonics an outperform vote. CompanyUnderperformOutperformArtivionOutperform Votes2177.78% Underperform Votes622.22% AxonicsOutperform Votes17466.67% Underperform Votes8733.33% Which has better earnings and valuation, AORT or AXNX? Axonics has higher revenue and earnings than Artivion. Axonics is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtivion$354M3.17-$30.69M-$0.21-127.38Axonics$408.81M8.80-$6.09M-$0.04-1,759.25 SummaryArtivion and Axonics tied by winning 9 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Artivion News Delivered to You Automatically Sign up to receive the latest news and ratings for AORT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AORT vs. The Competition Export to ExcelMetricArtivionSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$1.12B$4.45B$5.39B$19.27BDividend YieldN/A42.37%5.13%3.54%P/E Ratio-127.3838.29113.8141.53Price / Sales3.1765.071,483.2514.66Price / Cash34.6649.1039.6420.85Price / Book3.894.264.665.39Net Income-$30.69M$11.52M$119.06M$985.39M7 Day Performance1.06%1.05%0.79%-0.70%1 Month Performance1.60%0.94%5.65%-0.97%1 Year Performance106.40%39.40%36.76%25.06% Artivion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AORTArtivion2.038 of 5 stars$26.75+1.6%$30.60+14.4%+107.6%$1.12B$354M-127.381,500Upcoming EarningsNews CoverageAXNXAxonics3.8039 of 5 stars$70.32+0.0%$71.00+1.0%+35.9%$3.59B$366.38M-1,757.56610Upcoming EarningsShort Interest ↓Positive NewsNVSTEnvista4.3067 of 5 stars$20.82-0.7%$20.63-0.9%-8.9%$3.58B$2.57B-2.6812,800Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageTMDXTransMedics Group4.2511 of 5 stars$84.66+3.3%$144.80+71.0%+116.6%$2.84B$241.62M90.06210Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageNARIInari Medical3.1953 of 5 stars$48.45+0.1%$58.89+21.5%-20.6%$2.84B$493.63M-35.891,300Analyst ForecastInsider SellingAnalyst RevisionLIVNLivaNova4.2909 of 5 stars$51.66+0.1%$69.17+33.9%+2.2%$2.81B$1.15B123.002,900Analyst ForecastNews CoverageENOVEnovis2.955 of 5 stars$42.05+1.9%$67.00+59.3%-5.8%$2.35B$1.71B-25.336,550Upcoming EarningsIRTCiRhythm Technologies3.0679 of 5 stars$74.65+3.1%$111.60+49.5%-4.9%$2.33B$492.68M-15.362,000Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageSLNOSoleno Therapeutics4.2995 of 5 stars$56.17+2.0%$69.86+24.4%+132.7%$2.18BN/A-23.0230Upcoming EarningsCNMDCONMED4.8097 of 5 stars$69.71+2.2%$79.80+14.5%-28.7%$2.15B$1.24B16.564,000Earnings ReportAnalyst ForecastNews CoverageTNDMTandem Diabetes Care4.5349 of 5 stars$32.00+2.0%$55.13+72.3%+79.8%$2.09B$747.72M-15.312,400Upcoming EarningsPositive News Related Companies and Tools Related Companies Axonics Competitors Envista Competitors TransMedics Group Competitors Inari Medical Competitors LivaNova Competitors Enovis Competitors iRhythm Technologies Competitors Soleno Therapeutics Competitors CONMED Competitors Tandem Diabetes Care Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:AORT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artivion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
